Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-12-19
2003-06-03
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S374000, C514S380000
Reexamination Certificate
active
06573285
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the prevention or treatment of pain by administering an endothelin antagonist to a subject in need thereof.
BRIEF DESCRIPTION OF THE INVENTION
Endothelin-1 (ET-1) is a polypeptide with very potent vasoconstrictor activity. Elevated levels ET-1 are found in a variety of diseases including advanced prostate cancer and localized prostate cancer. It has been discovered that ET-1 not only functions as a vasoconstrictor but that it also has other functions, serving, for instance, as a growth factor alone or in combination with other hormones and peptides, as in prostate cancer (see, e.g.,
Nature Med.
1, 944-949, (1995)). In addition, as disclosed in WO 98/46076, ET-1 is related to the sorafotoxins, which are painful and lethal moieties in the venom of certain snakes of the genus Atractapsis. Similar to venom in a snake bite, recombinant ET-1 has been reported to produce intense pain in humans after the localized injection of high concentrations. Thus, for instance, in prostate cancer, a high localized concentration of ET-1 produced by the cancer cells is likely to be a major contributor to the high degree of pain associated with the late stage of the disease. Accordingly, molecules that prevent or inhibit the production of ET-1 can be expected to be useful to prevent and treat pain associated with elevated levels of endothelin.
Endothelin antagonists, which are compounds capable, inter alia, of inhibiting the binding of endothelin peptides to endothelin receptors, are useful in the treatment of endothelin-related disorders. While certain such compounds have been described as having utility in the treatment of hypertension, the present invention provides a method employing these compounds specifically for the treatment of pain.
REFERENCES:
patent: 5612359 (1997-03-01), Murugesan
patent: 6043265 (2000-03-01), Murugesan et al.
patent: WO 97/21445 (1997-06-01), None
patent: WO 99/56761 (1999-11-01), None
patent: WO 01/91736 (2001-12-01), None
Nelson, J.B. et al., BJU International, vol. 85, Supp. 2, pp. 45-48 (Apr. 2000).
Davar, G. et al., Neuroreport, vol. 9, No. 10, pp. 2279-2283 (Jul. 13, 1998).
Bristol-Myers Squibb Co.
Davis Stephen B.
Krass Frederick
LandOfFree
Method for preventing or treating pain by administering an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing or treating pain by administering an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing or treating pain by administering an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3100985